CAPITOL COUNSEL LLC for GENENTECH
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements. Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including advocacy related to the Most Favored Nation and related demonstration initiatives.
Foreign entity interest: Foreign parent affected by policies affecting U.S. subsidiary.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFFREY CARROLL | — |
| SHANNON FINLEY | — |
| ANN JABLON | — |
| JOHN MARTIN | — |
| CHARLES PATRICK MICHAELS | — |
Health Issues HCR
340B Program issues and patient access to pharmaceuticals. Legislative issues associated with patient access to treatment, including: the CMMI Most Favored Nation and related demonstration initiatives; and step therapy. Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains. Enhanced FDA reporting and risk mitigation plans for certain medicines. Incentives for antimicrobial and antiviral research, medical countermeasures, and novel product development.
Foreign entity interest: Foreign parent affected by policies affecting U.S. subsidiary.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFFREY CARROLL | — |
| SHANNON FINLEY | — |
| ANN JABLON | — |
| JOHN MARTIN | — |
| CHARLES PATRICK MICHAELS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.